EPISODE · Apr 28, 2021 · 15 MIN
Optimizing the Timing and Sequencing of Regorafenib and TAS-102 for Patients With Metastatic Colorectal Cancer
from Decera Clinical Education Oncology Podcast · host Joleen Hubbard MD, John Marshall MD
In this episode, Joleen Hubbard, MD, and John L. Marshall, MD, discuss use of the later-line treatment options regorafenib and TAS-102 for patients with mCRC, with topics including:Key data supporting the clinical use of these agentsOptimal sequencing and timing of useDosing considerationsKey adverse eventsPresenters:Joleen Hubbard, MDAssociate ProfessorGastrointestinal OncologistMedical OncologyMayo ClinicRochester, MinnesotaJohn L. Marshall, MDChief, Division of Hematology/OncologyDepartment of MedicineGeorgetown University HospitalWashington, DCContent based on an online CME program supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.Link to full program: BITLY NEEDED Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Embed this episode
What this episode covers
Listen to Joleen Hubbard, MD, and John L. Marshall, MD, discuss the use of key later-line treatment options for patients with mCRC, including optimal treatment sequencing and dosing and key adverse events.
NOW PLAYING
Optimizing the Timing and Sequencing of Regorafenib and TAS-102 for Patients With Metastatic Colorectal Cancer
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.